Estrella Immunopharma (NASDAQ:ESLA) Stock Price Up 1.3% – What’s Next?

Estrella Immunopharma, Inc. (NASDAQ:ESLA)’s share price rose 1.3% during trading on Thursday . The company traded as high as $1.6350 and last traded at $1.58. Approximately 272,307 shares changed hands during mid-day trading, an increase of 87% from the average daily volume of 145,470 shares. The stock had previously closed at $1.56.

Analysts Set New Price Targets

ESLA has been the subject of a number of research reports. D. Boral Capital reiterated a “buy” rating and set a $16.00 target price on shares of Estrella Immunopharma in a report on Monday, November 3rd. Wall Street Zen upgraded shares of Estrella Immunopharma to a “hold” rating in a research note on Saturday, November 22nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Estrella Immunopharma in a research report on Friday, October 31st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $16.00.

Estrella Immunopharma Stock Up 5.1%

The firm has a market capitalization of $62.70 million, a price-to-earnings ratio of -4.88 and a beta of 0.53. The stock has a 50 day moving average of $2.04 and a 200 day moving average of $1.35.

Estrella Immunopharma (NASDAQ:ESLA) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.